Seventeen children with vertically acquired hepatitis C virus (HCV) infection were followed from birth for a mean of 104 months. Alanine aminotransferase (ALT) levels were increased significantly at 3 and 6 months of age but were stable thereafter. HCV polymerase chain reaction was positive at 3 months in 16 patients and at 12 months in one patient. Viral load remained stable during followup at a mean value of 5.4 ± 0.4 log 10 . Mild chronic hepatitis was the most common histopathological feature on liver biopsy, occurring in six of the seven children biopsied at a mean age of 4.0 ± 2.4 years. Genotype did not seem to be related to the type of liver involvement. The results of this study suggest that vertically acquired HCV infection has a benign course in children, despite the presence of viraemia and persistent alterations in ALT levels.
Introduction
More than 170 million people (about 3% of the total population) are infected with hepatitis C virus (HCV) worldwide, 1 with 3 -4 million new infections occurring each year. The prevalence is approximately 0.2% in children and 0.4% in teenagers. Since post-transfusion hepatitis has almost disappeared, HCV transmission from an infected mother to her infant is now responsible for the majority of paediatric HCV infections in developed countries. The prevalence of HCVinfected pregnant women in Western Europe ranges from 0.2% to 2.4%. 2 The vertical transmission rate is about 5 -7%, but increases to 15% in HCV-infected mothers who are co-infected with human immunodeficiency virus (HIV). High maternal viral load and HIV co-infection are the main factors influencing the risk of transmission. 3 At present, there is no evidence that elective caesarean section reduces the HCV vertical transmission rate, and no evidence that breastfeeding significantly increases transmission, although the persistence of a minimal risk cannot be excluded. 2 -4 It is well known that, although the natural course of HCV infection in adults is to be slowly progressive, most remain asymptomatic for years. 5 Growing evidence seems to confirm a benign course for this disease in children also; the European Paediatric Hepatitis C Virus Network recently reported that about 20% of infected children clear the virus, while 80% of paediatric patients develop a chronic persistent infection. 6 While guidelines have been published on the treatment of HCV infection in adults, 5, 7, 8 experience with treating HCVinfected children is still very limited. 9 Interferon-α is not recommended for children < 3 years of age because of possible adverse effects on growth. 8 A review of published studies on interferon monotherapy in children found a 36% (range 0 -73%) sustained response rate (defined as negative for HCV on polymerase chain reaction testing at least 6 months after cessation of therapy). HCV genotype 1b is less responsive to interferon therapy; better results have been obtained with genotypes 2 and 3 and in patients with a low viraemic load. 10, 11 Data on the efficacy and safety of treatments, including interferon and ribavirin, in children are scarce. Combination therapy (interferon plus ribavirin) has been used in 11 children, with a sustained response in seven (64%) after 48 weeks' treatment. 12 The most effective treatment in adults is a combination of pegylated interferon and ribavirin. 13 Pegylation of interferon leads to a reduced renal clearance, a longer half-life and a prolonged plasma concentration, allowing it to be given as a single weekly injection. No data are available yet concerning the efficacy and safety of pegylated interferon in children.
We report here a longitudinal long-term follow-up study of children with vertically acquired HCV that aims to describe the natural course of vertically acquired HCV infection during the first two decades of life.
Patients and methods
Data were obtained from the case records of all children with vertically acquired HCV born at San Paolo Hospital, Milan, Italy, during the past 20 years (1984 -2005) .
Information concerning the mode of delivery, HIV co-infection and other comorbidity was recorded. Records of follow-up visits provided the results of clinical, biochemical and virological evaluation every 3 months for 2 years and every 6 months thereafter. Clinical evaluation included measurement of anthropometric parameters (height and weight), a complete physical examination and annual liver ultrasonograms. Liver biopsies were only performed when clinically indicated in selected patients. Virological investigations included anti-HCV enzyme-linked immunosorbent assay (ELISA), HCV polymerase chain reaction (PCR) testing and recombinant immunoblot assay (RIBA) (Vitros ® , Ortho-Clinical Diagnostics, Rochester, New York, USA) for immunometric confirmation. The Amplicor™ assay (Roche Diagnostics, Branchburg, NJ, USA) was used for qualitative HCV-RNA PCR before January 2000, and the quantitative PCR Cobas Amplicor™ HCV monitor (Roche) was used thereafter. Viral genotype was determined at the time of diagnosis by DNA hybridization in the solid phase using the INNO-LiPA HCV II assay (Innogenetics, Zwijnaarde, Belgium).
Infants born to mothers positive for anti-HCV were considered to be infected with HCV when HCV-RNA was detected in peripheral blood on PCR testing in at least two serum samples during the first year of life and/or positivity for anti-HCV persisted beyond 18 -24 months of life. 14, 15 Clearance of HCV from plasma was defined on the basis of PCR negativity at the last two tests, with normal alanine aminotransferase levels (< 40 IU/l) and the absence of clinical signs. 6 Artificial feeding was recommended when the level of HCV in the mother was > 4 × 10 5 IU/ml before delivery. 16 
DATA ANALYSIS
Descriptive analyses were carried out on the study population as a whole. Friedman's test and analysis of variance for repeated measures were used to compare individual parameters at different time-points, using Fisher's test for post-hoc comparison of two different time-points. Statistical analyses were performed using the SPSS ® Statistical Package for Windows, version 12.0 (SPSS Inc., Chicago, IL, USA). A P-value < 0.05 was considered to be statistically significant.
Results

PATIENTS
Over the past 20 years (1984 -2005) , 354 children were born at San Paolo Hospital to women infected with HCV, of which 17 (4.8%) were found to have acquired HCV. These 17 children (10 girls and seven boys) were followed from birth for an average of 104 months (range 9 -234 months); 14 (82.4%) were followed for 30 months or more, 11 (64.7%) were followed for 72 months or more, and seven (41.2%) were followed for 120 months or more.
The patients were all born at term; 16 were born vaginally and one was born by elective caesarean section for maternal indications. Thirteen of the 17 children were breastfed, data on the level of viraemia in the mother being unavailable. The child of a mother with a high level of viraemia (> 4 × 10 5 IU/ml) was artificially fed, as were three patients (17.6%) born to mothers positive for both HIV and HCV. These latter three patients were also monitored for HIV infection (using an anti-HIV ELISA and plasma HIV-1-RNA PCR); of the three, one was diagnosed as being co-infected with HIV and HCV on the basis of a positive HIV-1-RNA PCR in two consecutive blood tests (at 1 and 3 months of age).
On viral genotyping, genotype 1a was found in three of the 17 patients (17.6%), genotype 1b in three (17.6%), genotype 3a in eight (47.1%), genotype 4c/4d in two (11.8%) and genotype 2a/2c in one, HIV co-infected patient (5.9%). None of the patients received specific antiviral therapy for HCV.
SIGNS AND SYMPTOMS OF INFECTION
All children showed adequate growth. The only HCV-related sign was mild hepatomegaly in six of the 17 children (35.3%). None of the patients had splenomegaly or extrahepatic HCV-related findings.
ALANINE AMINOTRANSFERASE LEVELS
Alanine aminotransferase (ALT) levels at birth were within the normal range (< 80 IU/l) in all patients. The mean (± SD) level increased to 67 ± 42 IU/l by 3 months of age, with a further increase to 95 ± 71 IU/l by 6 months (P < 0.05), was then stable up to the age of 15 months and then increased to a peak of 156 ± 169 IU/l at 21 months (Fig. 1 ). After that, levels fell by 24 months and subsequently became stable at a mean of 105 ± 85 IU/l (Figs 1 and 2 ).
VIRAEMIA
At birth, HCV-RNA was negative for all children, but was positive in 16 of the 17 children (94.1%) at 3 months. One patient did not become HCV-RNA positive until 12 months of age.
For 10 of the 17 children (58.8%), the level of viraemia was only recorded after January 2000, owing to the unavailability of quantitative PCR before this time. Three further children (17.6%) were born after January 2000 and so were studied using quantitative PCR from birth. The remaining four children (23.5%) were lost to follow-up before the introduction of quantitative PCR.
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Using January 2000 as the baseline, the viral load expressed as the mean (± SD) logarithmic value of HCV-RNA was 5.4 ± 0.4 log 10 ; there were no significant changes in the viral load during the follow-up period (Fig. 3 ).
One child (5.9%), who had HCV genotype 1a, cleared the virus during the follow-up period. This patient had a positive PCR (quantitative PCR was not available) for 3 years and ALT levels consistently above 
HEPATIC ULTRASONOGRAPHY AND LIVER BIOPSY
The most frequent findings on hepatic ultrasonography were hepatomegaly and steatosis; no hepatic fibrosis was found. Seven of the 17 patients (41.2%) developed mild hepatomegaly at a mean (± SD) age of 4.5 ± 2.1 years. In contrast, steatosis was found later in nine patients (52.9%) at a mean age of 6.7 ± 3.2 years; of these nine, two children were infected with HCV genotype 2a/2c, two with genotype 1a, four with genotype 3a and one with genotype 1b.
Liver biopsy was performed in seven of the 17 children at a mean (± SD) age of 4.0 ± 2.4 years. Mild chronic hepatitis was found in six of the seven children biopsied: five were infected by HCV genotype 3a and one by genotype 1a. In the seventh child (genotype 4c/4d), the biopsy, performed at 1 year of age, showed mild fibrosis and steatotic hepatitis on histological examination.
CO-INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUS
One patient was diagnosed as being coinfected with HIV and HCV. The child remained asymptomatic (no HIV-and/or HCV-related signs or symptoms) during the whole follow-up period. At birth he had normal ALT values and a negative HCV-RNA PCR, but both ALT values and viraemia were high from 3 months of age. The patient was given antiretroviral therapy with lamivudine and zidovudine from 10 months. Between the ages of 12 and 21 months, the HCV viraemia declined consistently (from 596 000 IU/ml at 12 months to 19 000 IU/ml at 15 months and 680 IU/ml at 21 months) and the ALT levels reverted to the normal range. Antiretroviral therapy was associated 
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with a decline in HIV replication and minor liver damage, and also produced temporary immune reconstitution in terms of the CD4+ T-lymphocyte subset, allowing for better control of the HCV infection. After 21 months the patient relapsed due to failure of the antiretroviral therapy; the HCV-RNA PCR values increased to 543 000 IU/ml and remained stable at these high levels thereafter.
Discussion
Only a few reports have been published to date on the natural course of vertically acquired HCV infection in children. 6, 17 Anecdotal reports and clinical experience suggest that this disease has a benign course during the first two decades of life, but it is still unclear whether the natural history of HCV infection in infants is similar to that in adults.
The mode of delivery for HCV-infected women was a major concern in the 1990s due to the possibility of HCV transmission during vaginal delivery. In the absence of published data, elective caesarean section has never been recommended at our hospital for HCV-infected women, irrespective of viraemia levels, and the reported transmission rate at our hospital is similar to that in other published reports. Two large, retrospective studies have shown that vaginal delivery is not associated with an increased risk of HCV vertical transmission. In a recent paper published by the European Paediatric Hepatitis C Virus Network on 1479 mother-infant pairs, 3 no significant difference was found in the transmission rate between vaginal and caesarean delivery, and similar results were obtained in an Italian retrospective multi-centre study involving 1372 mother-infant pairs. 18 In the absence of sufficient information on the risk rate of HCV transmission through breastfeeding, in the present study we recommended formula feeding for children whose mothers had a high viraemic load (> 4 × 10 5 IU/ml) before delivery, as discussed elsewhere. 16 This view is not universal; although HCV has been isolated in human milk, a significant association has never been found between the type of infant feeding and the vertical transmission of HCV. 3, 18 At birth, HCV-RNA was negative in all our patients, confirming data reported by others. 19 The test became positive by 3 months of age, with the exception of one child who remained negative up to 12 months , but this patient had presented with high ALT levels since the age of 3 months. These results could be caused by the small quantity of circulating virus during the first few months of life in an infant with recent acute infection, together with the suboptimal sensitivity of the PCR test (sensitivity 97%; lower limit of detection 100 IU/ml). 20 Once quantitative HCV-RNA PCR became available at our laboratory in January 2000, we were able to demonstrate substantial stability in HCV viraemic levels in children with vertically acquired infection. This stability was also confirmed in individual children, with the exception of the patient co-infected with HIV.
There was a progressive increase in ALT levels up to the second year of life, followed by a stabilization of values at a lower level through subsequent years. Changes in the ALT values were not linked to significant variations in viraemia or clinical condition. Levels fluctuated widely in all the children studied, and did not correlate with HCV-RNA PCR values. These findings are consistent with previous observations 19, 21 and suggest the possibility of an interaction between the virus and the host in the natural course of the disease.
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Only one of the seventeen patients studied (5.9%) eliminated the virus (HCV genotype 1a); this patient had ALT values that were consistently above the normal range. These observations are consistent with those of Resti et al., 21 who concluded that high ALT levels during the first year of life are associated with a higher probability of HCV clearance, even though ALT levels are not a predictive factor for the patient's outcome. Data from the literature show that the viral clearance rate in children is about 15 -20%, with the remaining 80% staying chronically infected, 6, 22, 23 which is similar to adults. 5 Thus the age at acquisition of infection may not be a relevant factor for the persistence of HCV.
Patients with steatosis had various viral genotypes; owing to the small number of patients, it was not possible to associate a particular viral genotype with this type of liver damage. In addition, higher ALT levels did not seem to be associated with higher viral load and/or hepatomegaly. This points to the central role of the patient's immune response in the course of the disease. Liver biopsy, performed in seven patients, confirmed the relative benign nature of infection in children. 24 The course of HIV/HCV co-infection in children is only partially known since the natural history is often obscured by the need for antiretroviral therapy. The few published data, however, seem to confirm the largely benign course of the disease in spite of high ALT values and a high level of viraemia. 25 The potential hepatotoxicity of antiretroviral drugs is an important challenge for clinicians caring for HIV/HCV co-infected patients. Rodriguez-Rosado et al. 25 demonstrated that chronic HCV infection was associated with a 2.8 times greater risk of cytotoxicity in patients receiving triple antiretroviral therapy consisting of two nucleoside analogues and a protease inhibitor.
The results of the present study suggest that HCV has a benign and asymptomatic course in children, characterized by slow progression, even in the presence of viral replication and a steady alteration in liver necrosis indexes. We recommend that, in the light of the benign course of HCV infection and the lack of information on the efficacy and safety of therapy with interferon and ribavirin in infants and children, specific treatment for HCV infection should not be given until adolescence.
